This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 17126 results found since Jan 2013.
Comment on "Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib"
Br J Dermatol. 2023 Sep 8:ljad323. doi: 10.1093/bjd/ljad323. Online ahead of print.NO ABSTRACTPMID:37681491 | DOI:10.1093/bjd/ljad323
Source: The British Journal of Dermatology - September 8, 2023 Category: Dermatology Authors: Michael G Buontempo Kristen Lo Sicco Jerry Shapiro Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Comment on "Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib"
Br J Dermatol. 2023 Sep 8:ljad323. doi: 10.1093/bjd/ljad323. Online ahead of print.NO ABSTRACTPMID:37681491 | DOI:10.1093/bjd/ljad323
Source: The British Journal of Dermatology - September 8, 2023 Category: Dermatology Authors: Michael G Buontempo Kristen Lo Sicco Jerry Shapiro Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
Review of Baricitinib in the Treatment of Alopecia Areata
DISCUSSION: Baricitinib is the first FDA-approved treatment for AA. Other treatments for AA are used off-label with variable efficacy. Baricitinib is associated with black-box warnings due to adverse effects (AEs) associated with other Janus Kinase (JAK) inhibitors or use in other diseases. In the two large AA trials, AEs were considered mild or moderate; those reported more often with baricitinib than placebo included acne, elevations of low- and high-density lipoprotein cholesterol, and elevation of creatinine kinase. Baricitinib is a relatively tolerable and safe therapeutic alternative for severe AA, although additiona...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Singh Marcia S Driscoll Source Type: research
A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia
We report a 91.7% negative hair pull rate in the PRP treatment group which was significantly greater than the 69.4% negative hair pull rate in the minoxidil-treated group. Our study suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for treating AGA, especially in our patient demographic. These results have the opportunity to improve patient compliance and overall satisfaction while offering an improved option in patients unsatisfied with topical minoxidil. Citation: Shah R, Asim M, Ouellette S, et al. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% top...
Source: Journal of Drugs in Dermatology - September 8, 2023 Category: Dermatology Authors: Rohan Shah Mehmood Asim Samantha Ouellette Shawana Sharif Amar Shah Babar Rao Source Type: research
